FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130537353> ?p ?o ?g. }

• W2130537353 endingPage "1188" @default.
• W2130537353 startingPage "1169" @default.
• W2130537353 abstract "Incubation of resting lymphoid cells with recombinant interleukin 2 (IL-2) in vitro leads to the generation of lymphokine activated killer (LAK) cells capable of lysing fresh tumor cell suspensions in short-term chromium-release assays. Our previous studies (7) have demonstrated that the injection of LAK cells plus low doses of recombinant IL-2 were capable of inhibiting the growth of pulmonary metastases. We have now explored the ability of high doses of recombinant IL-2, administered systemically, to generate LAK cells in vivo, and to mediate antitumor effects directly. Administration of increasing doses of recombinant IL-2 intraperitoneally resulted in the generation of LAK cells in the spleens of recipient mice. Doses of 100,000 U recombinant IL-2 administered intraperitoneally approximately every 8 h for 5 d were capable of dramatically inhibiting established 3-d pulmonary metastases from the MCA-105 and MCA-106 syngeneic sarcomas and the syngeneic B16 melanoma in C57BL/6 mice. Grossly visible metastases present at 10 d after tumor injection also underwent regression following IL-2 therapy. Surprisingly, established 10 d pulmonary metastases were more susceptible to the effects of IL-2 than were the smaller 3 d pulmonary metastases. All antitumor effects of the systemic administration of recombinant IL-2 were eliminated if mice received prior treatment with 500 rad total body irradiation. The administration of high doses of recombinant IL-2 was also capable of inhibiting the growth of 3-d established subcutaneous tumors from the MCA-105 sarcoma, and of mediating the inhibition of growth and regression of established palpable subcutaneous MCA-105 sarcomas. Lymphocytes, which appeared morphologically to be activated, were present at the site of regressing tumor, and it appears that the mechanism of the antitumor effect of recombinant IL-2 administered systemically is via the generation of LAK cells in vivo, although this hypothesis remains to be proven. The ready availability of high doses of recombinant human IL-2, and the demonstration of antitumor effects seen in animal models have led us to the initiation of the clinical trials of recombinant IL-2 in humans." @default.
• W2130537353 created "2016-06-24" @default.
• W2130537353 creator A5004554374 @default.
• W2130537353 creator A5011289656 @default.
• W2130537353 creator A5050049473 @default.
• W2130537353 creator A5069061147 @default.
• W2130537353 creator A5072133376 @default.
• W2130537353 date "1985-05-01" @default.
• W2130537353 modified "2023-10-06" @default.
• W2130537353 title "Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2." @default.
• W2130537353 cites W1485716528 @default.
• W2130537353 cites W1501496773 @default.
• W2130537353 cites W1503279754 @default.
• W2130537353 cites W1546679468 @default.
• W2130537353 cites W1547930982 @default.
• W2130537353 cites W1563612582 @default.
• W2130537353 cites W1581613819 @default.
• W2130537353 cites W1583546728 @default.
• W2130537353 cites W1605214566 @default.
• W2130537353 cites W1633669131 @default.
• W2130537353 cites W1783973309 @default.
• W2130537353 cites W1882520884 @default.
• W2130537353 cites W1893785002 @default.
• W2130537353 cites W1906112488 @default.
• W2130537353 cites W1955661374 @default.
• W2130537353 cites W1976907391 @default.
• W2130537353 cites W1979687401 @default.
• W2130537353 cites W2012913493 @default.
• W2130537353 cites W2014113952 @default.
• W2130537353 cites W2036275492 @default.
• W2130537353 cites W2043621456 @default.
• W2130537353 cites W2046544299 @default.
• W2130537353 cites W2051962533 @default.
• W2130537353 cites W2066993291 @default.
• W2130537353 cites W2081219792 @default.
• W2130537353 cites W2102251060 @default.
• W2130537353 cites W2133818380 @default.
• W2130537353 cites W2143594378 @default.
• W2130537353 cites W2153784269 @default.
• W2130537353 cites W2157953677 @default.
• W2130537353 cites W2420056077 @default.
• W2130537353 doi "https://doi.org/10.1084/jem.161.5.1169" @default.
• W2130537353 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2187617" @default.
• W2130537353 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3886826" @default.
• W2130537353 hasPublicationYear "1985" @default.
• W2130537353 type Work @default.
• W2130537353 sameAs 2130537353 @default.
• W2130537353 citedByCount "703" @default.
• W2130537353 countsByYear W21305373532012 @default.
• W2130537353 countsByYear W21305373532013 @default.
• W2130537353 countsByYear W21305373532014 @default.
• W2130537353 countsByYear W21305373532015 @default.
• W2130537353 countsByYear W21305373532016 @default.
• W2130537353 countsByYear W21305373532017 @default.
• W2130537353 countsByYear W21305373532018 @default.
• W2130537353 countsByYear W21305373532019 @default.
• W2130537353 countsByYear W21305373532020 @default.
• W2130537353 countsByYear W21305373532021 @default.
• W2130537353 countsByYear W21305373532022 @default.
• W2130537353 countsByYear W21305373532023 @default.
• W2130537353 crossrefType "journal-article" @default.
• W2130537353 hasAuthorship W2130537353A5004554374 @default.
• W2130537353 hasAuthorship W2130537353A5011289656 @default.
• W2130537353 hasAuthorship W2130537353A5050049473 @default.
• W2130537353 hasAuthorship W2130537353A5069061147 @default.
• W2130537353 hasAuthorship W2130537353A5072133376 @default.
• W2130537353 hasBestOaLocation W21305373531 @default.
• W2130537353 hasConcept C104317684 @default.
• W2130537353 hasConcept C126322002 @default.
• W2130537353 hasConcept C129374314 @default.
• W2130537353 hasConcept C150903083 @default.
• W2130537353 hasConcept C203014093 @default.
• W2130537353 hasConcept C207001950 @default.
• W2130537353 hasConcept C25938499 @default.
• W2130537353 hasConcept C2776090121 @default.
• W2130537353 hasConcept C2776390293 @default.
• W2130537353 hasConcept C2777371288 @default.
• W2130537353 hasConcept C2777658100 @default.
• W2130537353 hasConcept C2778690821 @default.
• W2130537353 hasConcept C28651165 @default.
• W2130537353 hasConcept C40767141 @default.
• W2130537353 hasConcept C49382859 @default.
• W2130537353 hasConcept C502942594 @default.
• W2130537353 hasConcept C55493867 @default.
• W2130537353 hasConcept C71924100 @default.
• W2130537353 hasConcept C86803240 @default.
• W2130537353 hasConcept C8891405 @default.
• W2130537353 hasConcept C98274493 @default.
• W2130537353 hasConceptScore W2130537353C104317684 @default.
• W2130537353 hasConceptScore W2130537353C126322002 @default.
• W2130537353 hasConceptScore W2130537353C129374314 @default.
• W2130537353 hasConceptScore W2130537353C150903083 @default.
• W2130537353 hasConceptScore W2130537353C203014093 @default.
• W2130537353 hasConceptScore W2130537353C207001950 @default.
• W2130537353 hasConceptScore W2130537353C25938499 @default.
• W2130537353 hasConceptScore W2130537353C2776090121 @default.
• W2130537353 hasConceptScore W2130537353C2776390293 @default.
• W2130537353 hasConceptScore W2130537353C2777371288 @default.

• next